Go offline with the Player FM app!
Discovery of new HER2 inhibitors offers hope for treatment of non-small cell lung cancer
Manage episode 358022326 series 2680968
Lung cancer accounts for one of the highest numbers of cancer related deaths, and - among its disease subtypes - HER2 mutations can play a key role in tumour initiation and growth. Unfortunately no targeted therapy is yet available to treat the most common HER2 mutations.
Dr Birgit Wilding, Dr Ralph Neumueller, Dr Flavio Solca, and colleagues at Boehringer Ingelheim have been researching these HER2 mutations, and have developed drugs that inhibit the abnormal HER2 signalling driving cancer growth. One of the new inhibitors is now undergoing testing in a Phase 1 clinical trial to safely assess the potential of the drug as effective against tumours, and also reducing side-effects.
Read the original research : https://doi.org/10.1038/s43018-022-00412-y
354 episodes
Manage episode 358022326 series 2680968
Lung cancer accounts for one of the highest numbers of cancer related deaths, and - among its disease subtypes - HER2 mutations can play a key role in tumour initiation and growth. Unfortunately no targeted therapy is yet available to treat the most common HER2 mutations.
Dr Birgit Wilding, Dr Ralph Neumueller, Dr Flavio Solca, and colleagues at Boehringer Ingelheim have been researching these HER2 mutations, and have developed drugs that inhibit the abnormal HER2 signalling driving cancer growth. One of the new inhibitors is now undergoing testing in a Phase 1 clinical trial to safely assess the potential of the drug as effective against tumours, and also reducing side-effects.
Read the original research : https://doi.org/10.1038/s43018-022-00412-y
354 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.